| INTRODUCTION
The IQ motif and Sec7 domain 2 (IQSEC2) gene (OMIM #300522), located at chromosome Xp11. 22 , has recently been identified as an important neurodevelopment gene by next-generation sequencing studies. A total of 85 cases or families with IQSEC2 variants have been previously described in the medical literature; however, detailed case studies of only about 30 patients with IQSEC2 variants have so far been reported, and the phenotype has not yet been fully delineated.
IQSEC2 was first ascertained as a gene of neurodevelopment in
2008 when a girl with infantile spasms, profound developmental delay and severe intellectual disability was found to have a chromosomal translocation, with a break point disrupting the first intron of IQSEC2. 1 Murine studies showed that the IQSEC2 protein (also known as BRAG1) is expressed in the central nervous system in early development.
1 IQSEC2 is one of the most abundant proteins in the post-synaptic density of glutaminergic neurons, more so than N-methyl-D-aspartate (NMDA) receptors or α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) receptors, implying that it
is of crucial importance in post-synaptic transmission. 2 The established features of patients with IQSEC2 variants are global developmental delay, intellectual disability, epilepsy, microcephaly, hypotonia, language regression, social communication deficits and stereotypical hand movements. 3 In one study, seven of nine patients with IQSEC2 variants who underwent magnetic resonance imaging (MRI) of the brain showed abnormal but non-specific MRI appearances. 4 Much of the literature on humans with IQSEC2 variants takes the form of sequencing and reporting variants in patients with epilepsy. In the present study, the largest deep phenotyping study to date, we present 14 new patients with IQSEC2 variants, identified through the Deciphering Developmental Disorders (DDD) study and further delineate the features of the IQSEC2-related disorder.
| MATERIALS AND METHODS
Patients with a wide range of neurodevelopmental problems were recruited to the DDD study, 5 with trio whole-exome sequencing performed as previously described. 6 All patients had had an uninformative chromosomal microarray prior to recruitment. The IQSEC2 (NM_001111125.2) variants identified were validated by targeted Sanger sequencing.
An application to the DDD study for a complimentary analysis project was successfully made, allowing access to anonymized details of patients with IQSEC2 variants identified through DDD on the Decipher website. 7 The clinicians of selected patients were contacted to invite patients and their families to be recruited. Excluded from the study were: patients with an additional proven genetic diagnosis, those with a chromosomal anomaly and those in whom IQSEC2 variants were of unknown inheritance or unknown clinical significance, with the exception of two cases where the clinician had a high degree of suspicion that the variant was causative.
The clinical significance of the variants identified was interpreted according to the guidelines set out by the American College of Medical Genetics. 8 Written consent for patients' clinical details and photographs to be used in journal publication was provided by the parents of the patients.
| RESULTS
Fourteen patients with variants in the IQSEC2 gene were recruited.
Seven were reviewed in the clinic for deep phenotyping by the first author and the responsible clinician. For the others, comprehensive data were collected from the responsible clinicians. Clinical information for each patient is detailed in Appendix S1, supporting
Information.
Eight recruits were female, and six were male. Eleven had a de novo variant, and one had a maternally inherited variant. Two patients were monozygotic twins. Two patients were brothers, but the IQSEC2 variant was not identified in their mother's blood sample. Ten recruits were reported as having a pathogenic, or likely pathogenic, variant, and two had a variant reported as being of uncertain clinical significance but with a phenotype consistent with that of the IQSEC2-related disorder and suspected by the responsible clinician to be causative of the disorder.
Among this cohort, there were no consanguineous parental unions. There was an increase in nuchal translucency in one case. Two recruits were born at 36 weeks' gestation, and the remaining singletons were born at 37 to 42 weeks' gestation. All singleton recruits had birth weights between the 9th and 99th centiles. Their postnatal heights were variable, between the 0.4th and 75th centiles. X inactivation studies on patients 6 and 7 and the mother of patient 5 showed no evidence of skewed X inactivation.
Features of patients in this cohort are summarised in Table 1 .
Photographs of the patients are shown in Figure 1 . including one who required a gastrostomy. 13 The findings, considered together with previous reports, suggest that these features probably form part of the IQSEC2-related disorder. The requirement for gastrostomy feeding in two patients in this cohort was probably because of a combination of developmental delay/intellectual disability, hypotonia and oral motor dysfunction. These patients did not have early feeding difficulties, implying that early feeding difficulties are not an indicator of the likelihood of requiring gastrostomy feeding later in childhood in the IQSEC2-related disorder.
Plagiocephaly, cortical blindness and strabismus were also found in 16.7% of this cohort and may be associated with the disorder.
Among individuals with IQSEC2 variants, cortical blindness has been reported in one patient previously 9 ; plagiocephaly has been previously reported in two patients, 9 and strabismus has previously been reported in 16 individuals, 1, 4, [9] [10] [11] [13] [14] [15] Constipation, gastro-oesophageal reflux and eczema, while common in all children, appeared to be over-represented in recruits to this study. Among individuals with IQSEC2 variants, gastro-oesophageal reflux has only been reported in one case, 15 and constipation and eczema have not been reported, but data from this study support an association.
Many patients did not have their occipital frontal circumference (OFC) at birth documented. However, patients 2, 10, 12 and 14, who had serial OFC measurements in their early childhood, show a 'crossing of the centiles' towards the 0.4th centile and provide evidence that the microcephaly seen in the IQSEC2-related disorder is, at least in some cases, secondary microcephaly. This is consistent with a previous report. 13 IQSEC2 not known to be of functional importance. Previously, missense variants have been reported in males with severe intellectual disability but not seizures. 11, 17 The fact that the mother of patient 5 (with normal intelligence) had a normal X inactivation pattern does not exclude pathogenicity of his variant because inheritance of the IQSEC2 missense variant from a non-epileptic, normal intelligence female has been reported. 13 as has inheritance from females with only mild learning difficulties. [16] [17] [18] [19] The variants of patients 1 and 5 have not been previously reported, and there does remain some uncertainty as to their pathogenicity. However, many IQSEC2 missense variants in regions not known to be functional have been described in patients with intellectual disability, with or without epilepsy. 16 If these variants are shown to be causative of their disorder, then this implies that there exist other, as yet unrecognised, important functional domains of the IQSEC2 protein.
| Explaining the female IQSEC2 phenotype
It has been challenging to find an explanation for the IQSEC2 phenotype in females 4, 16 given that females can have a severe phenotype, despite having a 'back up' X chromosome. It has been suggested that, in females, haploinsufficiency is sufficient to produce the full phenotype, or alternatively, these variants produce a dominant negative effect. These mechanisms imply X-linked dominance, so it is difficult to explain then how some females with IQSEC2 missense variants have a normal or near-normal phenotype, which would imply X-linked recessive inheritance. This raises the possibility that IQSEC2 variants can show X-linked-dominant or X-linked-recessive inheritance, and this may depend on the type of variant (missense vs nonsense or frameshift).
IQSEC2 is widely quoted in the literature to 'escape' X inactivation (ie, is expressed from both copies of the X chromosome in females)
based on the findings of Tsuchiya et al. 20 and Cotton et al, 21 although
IQSEC2 is not specifically mentioned in these papers. This view seemed to be in agreement with the finding that IQSEC2 is expressed in very similar levels in human female and male brains. 22 However, other work had shown that IQSEC2 is X-inactivated, 23 and X inactivation studies cast doubt on the escape theory. Of the four patients in the literature where X inactivation studies have been performed on samples of females with IQSEC2 variants, one had unfavourable skewing of 100:0 in blood, 1 two others had severely unfavourably skewed X inactivation (100:0 and 97:3), 4 and a fourth had normal (66:34) X inactivation. 4 That skewed X-inactivation is a principal moderator of phenotype in a IQSEC2-related disorder was not supported by the results of X inactivation studies performed on patients 6 and 7 and of the mother of patient 5 in this study. However, this is a small sample size, and these results may not reflect the pattern of X inactivation in other tissues. It may be that IQSEC2 may be variably inactivated, 16 as is known to be the case for many other genes.
| The IQSEC2-related disorder mimics other syndromes
There is a well-documented similarity in the phenotype of individuals with IQSEC2 variants and Rett syndrome. 4, 11, 24 In agreement with this, five patients (35.7%) of this cohort had had MECP2 analysis prior to the identification of the IQSEC2 variant.
Other genes noted to have a phenotypic overlap with the IQSEC2-related disorder include FOXG1, CDKL5 and MEF2C. 24 Consistent with this was the fact that one sample from this cohort had IQSEC2 is included on some, but not all, developmental delay gene panels or subpanels available in the United Kingdom. Most epilepsy panels do not include IQSEC2. 25 The addition of IQSEC2 to these panels will probably reveal more cases of the IQSEC2-related disorder.
| Gonadal mosaicism
The finding of the same IQSEC2 variant in samples from patients 13 and 14 but not their mother's sample implies that their mother displays gonadal mosaicism for the IQSEC2 variant. There has been one previous report of gonadal mosaicism in a family with the IQSEC2-related disorder. 26 We therefore recommend that parents of a child with the IQSEC2-related disorder should be counselled for the potential of gonadal mosaicism and the potential recurrence risk (which currently cannot be quantified) in subsequent pregnancies.
| Twin phenotype discordance
The phenomenon of twin discordance for features of the IQSEC2-related disorder has not been reported previously. Patient 6 has profound intellectual disability with epilepsy and aggressive/self-injurious behaviour, whereas her monozygotic twin sister, patient 7, has a much milder phenotype, with the ability to attend a mainstream school until the age of 10 years. Indeed, patient 7 had never been referred to a community paediatrics or genetics clinic prior to the identification of the IQSEC2 variant in her twin sister. The twins were also discordant for other features distinct from the IQSEC2 phenotype, namely, birth weight, face shape, patency of the ductus arteriosus and weight.
Monozygotic twins are not truly identical, and X inactivation and imprinting are known to be discordant in some monozygotic twin Twin non-concordance can, in some cases, be explained by the non-equal allocation to each twin of stem cells after formation of the blastomere, 27 which may have important implications for the cascade of developmental events during embryogenesis. 30 Weksberg et al.
30
hypothesise that post-zygotic events may lead to the formation of two or more cell clones in the inner cell mass of the embryo and that this actually precipitates the twinning event. Other potential explanations for twin discordance in this cohort include post-zygotic or somatic single-nucleotide polymorphisms that either directly, and coincidentally, affect IQSEC2 or proteins with which it interacts or themselves cause the alteration of epigenetic marks. 29 The observation that DNA methylation profiles are less alike within pairs of monochorionic, monozygotic twins compared to pairs of dichorionic, monozygotic twins suggests that sharing a placenta may cause unequal conditions in foetal life and therefore more discordant epigenetic profiles. 29 It is whether or not the putative twin-to-twin transfusion syndrome seen in these twins played a role in differing epigenetic profiles or contributed to the disparity in phenotype.
| Future Therapies
Recently, the goal of curing genetic diseases has edged closer to becoming a reality, with the discovery and utilisation of the clustered regularly interspaced short palindromic repeats (CRISPR) Cas9 system to repair missense variants and cure genetic disease. 31 The finding that the shorter IQSEC2 isoform shows continued and increasing expression in postnatal life 32 offers hope that amelioration of the severity of the IQSEC2 phenotype may be possible by means of the repair of missense variants in IQSEC2 or using drug therapy to inhibit epigenetic marks.
The latter would depend on the identification of epigenetic marks that are capable of moderating the phenotype in this disorder. Secondary microcephaly in individuals with IQSEC2 variants implies a brain growth deceleration phase following birth (in at least some cases), meaning that there may be a window of opportunity early in life in which to treat these individuals with any such targeted therapy.
| CONCLUSION
The data from this study provide evidence for several new features of the IQSEC2-related disorder and support the notion of an emerging IQSEC2 syndrome. We echo a previous recommendation by Helm et al. 13 to consider requesting IQSEC2 analysis in all patients with severe intellectual disability and seizures or a phenotype resembling Rett syndrome. In addition, we suggest that, first, the possibility of the presence of an IQSEC2 variant is also considered in patients with an
Angelman-/Pitt-Hopkins-like phenotype and, secondly, that IQSEC2
should be added to epilepsy and developmental delay/intellectual disability panels. As whole exome and whole-genome sequencing become more widely available, it is probable that an increasing number of IQSEC2 variants will be identified.
The observation of apparent gonadal mosaicism in this cohort has implications for genetic counselling of parents with an affected child.
The observation of twin discordance in phenotype in this study offers hope for the possible development of a therapy to mitigate the severity of the IQSEC2 phenotype.
